Impact of the diagnostic delay of acromegaly on bone health: data from a real life and long term follow-up experience
- PMID: 35922724
- PMCID: PMC9362053
- DOI: 10.1007/s11102-022-01266-4
Impact of the diagnostic delay of acromegaly on bone health: data from a real life and long term follow-up experience
Abstract
Introduction: Acromegaly is a chronic disease with systemic complications. Disease onset is insidious and consequently typically burdened by diagnostic delay. A longer diagnostic delay induces more frequently cardiovascular, respiratory, metabolic, neuropsychiatric and musculoskeletal comorbidities. No data are available on the effect of diagnostic delay on skeletal fragility. We aimed to evaluate the effect of diagnostic delay on the frequency of incident and prevalent of vertebral fractures (i-VFs and p-VFs) in a large cohort of acromegaly patients.
Patients and methods: A longitudinal, retrospective and multicenter study was conducted on 172 acromegaly patients.
Results: Median diagnostic delay and duration of follow-up were respectively 10 years (IQR: 6) and 10 years (IQR: 8). P-VFs were observed in 18.6% and i-VFs occurred in 34.3% of patients. The median estimated diagnostic delay was longer in patients with i-VFs (median: 11 years, IQR: 3), in comparison to those without i-VFs (median: 8 years, IQR: 7; p = 0.02). Age at acromegaly diagnosis and at last follow-up were higher in patients with i-VFs, with respect to those without i-VFs. The age at acromegaly diagnosis was positively associated with the diagnostic delay (p < 0.001, r = 0.216). A longer history of active acromegaly was associated with a high frequency of i-VFs (p = 0.03). The logistic regression confirmed that patients with a diagnostic delay > 10 years had 1.5-folds increased risk of developing i-VFs (OR: 1.5; 95%CI: 1.1-2; p = 0.017).
Conclusion: Our data showed that the diagnostic delay in acromegaly has a significant impact on VF risk, further supporting the clinical relevance of an early acromegaly diagnosis.
Keywords: GH; GH secreting adenoma; IGF-1; Osteomalacia; Skeletal fragility; Vertebral fractures.
© 2022. The Author(s).
Conflict of interest statement
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this paper.
Figures




Similar articles
-
Cholecalciferol Use Is Associated With a Decreased Risk of Incident Morphometric Vertebral Fractures in Acromegaly.J Clin Endocrinol Metab. 2023 Dec 21;109(1):e58-e68. doi: 10.1210/clinem/dgad493. J Clin Endocrinol Metab. 2023. PMID: 37606222 Free PMC article.
-
Conventional X-rays in the diagnosis and follow-up of vertebral fractures in patients with acromegaly: a real-life study.J Endocrinol Invest. 2024 Feb;47(2):325-334. doi: 10.1007/s40618-023-02148-7. Epub 2023 Sep 5. J Endocrinol Invest. 2024. PMID: 37668886
-
Progression of vertebral fractures in long-term controlled acromegaly: a 9-year follow-up study.Eur J Endocrinol. 2020 Oct;183(4):427-437. doi: 10.1530/EJE-20-0415. Eur J Endocrinol. 2020. PMID: 32688336
-
Vertebral Fractures in Acromegaly: A Systematic Review.J Clin Med. 2022 Dec 25;12(1):164. doi: 10.3390/jcm12010164. J Clin Med. 2022. PMID: 36614962 Free PMC article. Review.
-
New tools for bone health assessment in secreting pituitary adenomas.Trends Endocrinol Metab. 2023 Apr;34(4):231-242. doi: 10.1016/j.tem.2023.01.006. Epub 2023 Mar 2. Trends Endocrinol Metab. 2023. PMID: 36869001 Review.
Cited by
-
New insights into the vitamin D/PTH axis in endocrine-driven metabolic bone diseases.Endocrine. 2024 Sep;85(3):1007-1019. doi: 10.1007/s12020-024-03784-6. Epub 2024 Apr 17. Endocrine. 2024. PMID: 38632163 Review.
-
Standards of care for medical management of acromegaly in pituitary tumor centers of excellence (PTCOE).Pituitary. 2024 Aug;27(4):381-388. doi: 10.1007/s11102-024-01397-w. Epub 2024 Jun 4. Pituitary. 2024. PMID: 38833044 Free PMC article.
-
Acromegaly and Bone: An Update.Endocrinol Metab (Seoul). 2023 Dec;38(6):655-666. doi: 10.3803/EnM.2023.601. Epub 2023 Dec 22. Endocrinol Metab (Seoul). 2023. PMID: 38164073 Free PMC article. Review.
-
Pilot study to define criteria for Pituitary Tumors Centers of Excellence (PTCOE): results of an audit of leading international centers.Pituitary. 2023 Oct;26(5):583-596. doi: 10.1007/s11102-023-01345-0. Epub 2023 Aug 28. Pituitary. 2023. PMID: 37640885 Free PMC article.
-
Skeletal fragility in pituitary disease: how can we predict fracture risk?Pituitary. 2024 Dec;27(6):789-801. doi: 10.1007/s11102-024-01447-3. Epub 2024 Sep 6. Pituitary. 2024. PMID: 39240510 Free PMC article. Review.
References
-
- Chiloiro S, Mirra F, Federico D, Giampietro A, Visconti F, Rossi L, Pontecorvi A, De Marinis L, Bianchi A. The role of growth hormone receptor isoforms and their effects in bone metabolism and skeletal fragility. Protein Pept Lett. 2020;27(12):1260–1267. doi: 10.2174/0929866527666200616151105. - DOI - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources